Yuyue Medical: The company's current production and operations are stable and orderly.

Securities Daily Network News. On April 6, Yuyue Medical, in response to an investor question on an interactive platform, stated that fluctuations in secondary market stock prices are influenced by multiple factors. The company’s current production and operations are stable and orderly. The company has always attached great importance to investor returns, has implemented cash dividends over the long term, and has steadily returned value to investors. In 2024, the company’s total cash dividend amounted to RMB 802 million, accounting for 44.40% of the net profit attributable to the company’s listed shareholders for 2024. Meanwhile, the company has actively increased the frequency of dividends and implemented dividends for the first half of 2025 and the first three quarters. In the future, the company will adhere to focusing on and deepening its core business. With global development, digital intelligence, and wearables as its core strategy, it will continue to enhance its capabilities in areas including research and development, production, and sales, promote the company’s long-term steady development, and actively do a good job in market value management to create long-term, sustainable returns for shareholders. If there are matters that require review and disclosure, the company will promptly fulfill review procedures and information disclosure obligations in accordance with relevant regulations.

(Editor: Ren Shibi)